Craig-Hallum initiated coverage of Akoya Biosciences with a Buy rating and $7.50 price target. The firm believes Akoya is at the front end of a significant product adoption cycle with the potential to be a $500M revenue company in five years. The shares are “significantly” undervalued, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Akoya Biosciences management to meet virtually with BTIG
- Akoya Biosciences price target lowered to $4 from $8 at Morgan Stanley
- Akoya Biosciences price target lowered to $6 from $9 at BTIG
- Canaccord cut Akoya target, sees buying opportunity on selloff
- Akoya Biosciences sees FY24 revenue 104M-$112M, consensus $115.77M